immuno-oncology

News

With all eyes on IO, Tagrisso could be AZ's ace card

AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.

Partner Content

Partner Content

Immuno-Oncology: A 360° View in NYC this February

The Conference Forum has announced that the 3rd annual

Views & Analysis

ESMO review: advances in immunotherapy, EMA dialogue and pa...

QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.

News

Three's a crowd as Tecentriq approved in lung cancer

Cancer immunotherapy approved in second line.

News

Adaptimmune revives ovarian cancer trial

T-cell trial will include controversial chemo agent fludarabine.

Partner Content

Partner Content

The next step in the fight against cancer: Making CAR-T a vi...

Four years ago, Emily Whitehead, who was just seven years old at the time, inadvertently became headline news as her previously incurable acute lymphoblastic leukaemia (ALL) moved into remission an

With all eyes on IO, Tagrisso could be AZ's ace card

Immuno-Oncology: A 360° View in NYC this February

ESMO review: advances in immunotherapy, EMA dialogue and pa...

Three's a crowd as Tecentriq approved in lung cancer

Adaptimmune revives ovarian cancer trial

The next step in the fight against cancer: Making CAR-T a vi...

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks